(Q82294993)
Statements
Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) (English)
Barbara Schmalfeldt
Michael Jäger
Alexandra Schoberth
Peter Ruf
Juergen Hess
Pauline Wimberger
Michael Ströhlein
Bettina Theissen
Markus M Heiss
Horst Lindhofer